NIFTY  8,879.20  0.65%
  SENSEX  28,661.60  0.68%
 CURRENCY  Rs  67.02/$ 71.15/€, 83.19/£
  GOLD  29,262.00  -0.33%
  SILVER  42,830.00  -0.25%
  DAX  11,757.00  -0.00%
  FTSE  7,299.96  0.30%
  CAC  4,867.58  -0.55%
  HANG SENG  24,146.10  0.47%
  NIKKEI  19,251.10  0.09%
  Shanghai Composite  3,239.96  0.65%
  DOW JONES  20,624.10  0.02%
  NASDAQ  5,838.58  0.41%
  S&P 500  2,351.16  0.17%
RUPEE AT CLOSE - Rupee Ends At 66.92/$ Vs 67.01/$ On Friday SIEMENS - Bags Order Worth Rs 287 Cr Form Nagpur Metro Rail Corporation

Lupin To Gain At Ranbaxy's Expense?

Video:

Play this video

February 6: Ranbaxy and Wockhardt's U.S. FDA troubles may spell good news for rival Lupin. Chief Executive Officer Vinita Gupta told Bloomberg that Lupin’s track record on quality and the overlap of drug portfolios with Indian rivals gives it an opportunity to add sales in the U.S. Bloomberg’s Ketaki Gokhale shares a detailed report on the same.